Bed & Breakfast No Brainer, page-22

Wise thinking from two longterm holders above.

Bio tech has never been a sprint, always an endurance test. Getting long overdue recognition with the mc increase in past couple of weeks is nice but it is still early days. MC under $500 million is nothing.

Really does sum up the mentality of the asx market, looking for a catalyst to be announced at the agm, whilst there is already an abundance of information in the public domain that warrants a 20c + sp.

ph 1 results, earlier idmc go ahead, a stunning pipeline to knock the sox off other juniors valued 3 times higher. Peers valued 10x higher with old hat tech.

i doubt the move from 7 to 11c was retail investors switching on,
it had all out the fingerprints of the instos getting themselves set, knowing its a bargain, this month, next month, next year. They certainly wont be giving back freebies next week.

13c should be tested with a minimum of fuss. 9c already a good base after seeing Friday's price action and strong demand toward the finish of trade with unsatisfied buyers still paying up.